<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439621</url>
  </required_header>
  <id_info>
    <org_study_id>2006-24</org_study_id>
    <nct_id>NCT00439621</nct_id>
  </id_info>
  <brief_title>Safety Study of Anti-IgE Immunotherapy in Allergic Patients</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Safety and Tolerability Study of Repeated Doses of Anti-IgE Immunotherapy in Allergic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Resistentia Pharmaceuticals AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Resistentia Pharmaceuticals AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate safety and efficacy of three doses and two dosing
      regimens of RP01 as an anti-IgE immunotherapy in allergic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunotherapy is based on the principle of eliciting an immune reaction in order to block the
      negative effect of a specific disease-causing protein. The potential to treat diseases by
      means of immunotherapy instead of using conventional drugs represents an attractive
      opportunity in a number of chronic disease areas, including asthma and allergy. Resistentia's
      model to treat allergic diseases, and ultimately asthma, is to use the immune system to
      produce antibodies against the IgE molecules themselves. The resulting anti-IgE antibodies
      intercept and form complexes with the IgE molecules before they can bind to the mast cells
      and basophils and are thus able to block any allergen-triggered inflammatory reaction. The
      approach works in all types of IgE-mediated allergies independently of allergen, and also in
      patients sensitive to multiple allergens.

      Comparisons: Three doses and two dosing regimes of RP01 will be compared as regards safety
      and effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>0-12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune kinetic parameters</measure>
    <time_frame>0-12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RP 01</intervention_name>
    <description>Active immunotherapy</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allergy to at least one aero allergen

          -  Increased serum IgE level

        Exclusion Criteria:

          -  Diagnosis of asthma

          -  Recent use of systemic corticosteroids or immunosuppressive treatment

          -  Allergy vaccination therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vidar Wendel-Hansen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Resistentia Pharmaceuticals AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2007</study_first_submitted>
  <study_first_submitted_qc>February 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2007</study_first_posted>
  <last_update_submitted>August 13, 2008</last_update_submitted>
  <last_update_submitted_qc>August 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2008</last_update_posted>
  <keyword>immunotherapy</keyword>
  <keyword>allergy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

